SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

2 marketing jobs

Tandem Diabetes Care logo
3 days ago

Director, Product Marketing; Integrated Systems

Tandem Diabetes Care

Red Bluff, CA (Hybrid)Full time$174K/yr – $222K/yr
Tandem Diabetes Care logo
4 days ago

Director, Product Marketing; Integrated Systems

Tandem Diabetes Care

Del Norte County, CA (Hybrid)Full time$174K/yr – $222K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

2 jobs
Tandem Diabetes Care logo

Director, Product Marketing; Integrated Systems

Tandem Diabetes Care

Red Bluff, CA (Hybrid)

$174K/yr - $222K/yrIn-houseFull-timeDirector/executive10+ years exp.
3 days ago
Tandem Diabetes Care logo

Director, Product Marketing; Integrated Systems

Tandem Diabetes Care

Del Norte County, CA (Hybrid)

$174K/yr - $222K/yrIn-houseFull-timeDirector/executive10+ years exp.
4 days ago
Tandem Diabetes Care logo
Tandem Diabetes Care

Director, Product Marketing; Integrated Systems

Red Bluff, CA (Hybrid)

$174K/yr – $222K/yrDirector/Executive10+ years expFull time

Posted 3 days ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own product marketing leadership for CGM integrations, Tandem Source, and Sugarmate by Tandem, driving strategy, positioning, launches and cross-functional execution across healthcare products.

  • Lead cross-functional product marketing and launches
  • Develop go-to-market and lifecycle plans

Job Description

Responsibilities

  • Provide direct leadership, coaching, and performance management for product marketing leaders responsible for CGM integrations, Tandem Source and Sugarmate by Tandem.
  • Lead product marketing strategy and planning across assigned business areas, ensuring alignment with product roadmaps, commercial objectives, and organizational priorities.
  • Develop and maintain product positioning, messaging, and go-to-market strategies that support product adoption, customer engagement, and business performance.
  • Partner with cross-functional stakeholders to support prioritization, launch readiness, lifecycle planning, and market development activities for assigned products.
  • Lead launch execution for assigned products by coordinating cross-functional workstreams, key milestones, and readiness activities to support successful commercialization.
  • Oversee product marketing plans across a portfolio of products and initiatives, balancing short-term business needs with longer-term strategic objectives.
  • Provide leadership for assigned products throughout the launch lifecycle, including planning, execution oversight, performance monitoring, and adjustment of plans based on market feedback and business results.
  • Lead market assessments, customer insight synthesis, and performance reviews to identify opportunities, risks, and recommended actions.
  • Collaborate with Commercial, Sales, Product, Clinical, and other cross-functional stakeholders to support effective execution against business goals and market needs.
  • Build organizational capability by strengthening team alignment, clarifying roles and responsibilities, and developing talent across the broader product marketing organization.

Requirements

  • Bachelor’s degree in business, health sciences, or a related field, or an equivalent combination of education and relevant experience.
  • 10+ years of related experience in marketing, product marketing, or product management.
  • 7+ years of leadership experience with visibility to senior management, including experience managing managers.
  • Demonstrated experience in product marketing, portfolio strategy, or commercial leadership within the healthcare, medical device, or pharmaceutical industry.
  • Demonstrated success as a cross-functional leader with strong knowledge of healthcare from provider, patient, and manufacturer perspectives.
  • Strong product marketing expertise across positioning, messaging, go-to-market planning, lifecycle management, and commercial execution.
  • Strong strategic thinking skills and the ability to develop and execute product marketing plans across product lines, customer segments, and geographies.
  • Excellent written, verbal, and presentation skills, with the ability to communicate effectively across cross-functional teams.
  • Strong experience in product management and/or product marketing, including requirements development, roadmap planning, portfolio strategy, new product development, product launch, and execution.
  • Strong project management skills, including the ability to prioritize and manage multiple initiatives simultaneously.

Preferred

  • General understanding of the diabetes industry is highly preferred.

Benefits

  • health care benefits such as medical, dental, vision available your first day, as well as health savings accounts and flexible saving accounts
  • 11 paid holidays per year
  • unlimited PTO
  • 401k plan with company match
  • Employee Stock Purchase plan
Tandem Diabetes Care logo

Tandem Diabetes Care

3.5 Glassdoor

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem is the #1 recommended insulin pump brand by people living with diabetes, four years and counting. (dQ&A US Diabetes Connections Patient Panel Report; Net Promoter Score; Q1 2019-Q3 2023: P.49, Q3 2023 (Jan. 2019-Sept. 2023). Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.SAFETY INFORMATION Please note that this account is not intended to be used for product support or medical advice. If you are having a medical emergency, please dial 911. If you are having an issue with one of our products and need immediate assistance, please call our 24-hour customer support team at 877-801-6901 and press 1 twice. RX ONLY. Indicated for patients with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 55 lbs. Safety info: tandemdiabetes.com/safetyinfo.

Founded in 2006
San Diego, California, USA
2.2K employees (63 in marketing)
www.tandemdiabetes.com
61% recommend to a friend
78% CEO approval

Salaries

Posted range

$174K/yr – $222K/yr

Taken straight from the job posting.

See all Tandem Diabetes Care salaries

Marketing Team

Marketing Team Size
40 (2% of company)
Median Tenure
4.5 years
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$641.5M
Last Raise
$275M
Post IPO Debt, 2 years ago

Funding History

  • Mar 2024
    Post IPO Debt • $275M
  • Aug 2018
    Post IPO Equity • $115M
  • Feb 2018
    Post IPO Equity • $69M

Traffic Signals

Monthly Visitors
390.1K
Monthly Google Ads Budget
$15.8K
Traffic Source Mix
Search
35.3%
Direct
59.2%
Referral
4.1%
Social
0.6%
Paid
0.7%

Headcount Trend

Current headcount: ~2.2K

Recent News

Tandem Diabetes Care (TNDM) Is Up 23.1% After FDA Clears Android App for Mobi System – Has the Bull Case Changed?
Nov 13, 2025 • Yahoo Finance
What the launch of Mobi for Android means for Tandem, people with diabetes
Nov 12, 2025 • Drug Delivery Business
Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors
Nov 12, 2025 • Yahoo Finance
Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors
Nov 12, 2025 • Morningstar
Tandem Diabetes Care's app cleared by the FDA for Android phones
Nov 10, 2025 • MobiHealthNews
Tandem Diabetes Care (TNDM): Assessing Valuation After Record Q3 Sales, Margin Gains, and New Innovation Boosts
Nov 9, 2025 • Yahoo Finance
Tandem Diabetes Care Announces Third Quarter 2025 Financial Results
Nov 6, 2025 • BioSpace
Tandem Diabetes Care Inc (TNDM) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ...
Nov 6, 2025 • Yahoo Finance
Tandem Diabetes Care Achieves ISO/IEC 27001:2022 Certification, Reinforcing Commitment to Global Data Security Standards
Nov 4, 2025 • Business Wire
Why Analysts Are Rethinking the Story Behind Tandem Diabetes Care After Recent Developments
Nov 2, 2025 • Yahoo Finance
Tandem Diabetes Care (TNDM): Examining the Valuation After a Challenging Year and Recent Rebound
Nov 1, 2025 • Sahm
Tandem Diabetes Care Announces Upcoming Conference Presentations
Oct 31, 2025 • Business Wire
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Oct 30, 2025 • Yahoo Finance
Tandem Diabetes Care Launches t:slim X2 Pump Integration with Abbott FreeStyle Libre 3 Plus Sensor
Oct 30, 2025 • HIT Consultant
Tandem launches t:slim X2 pump with Abbott FreeStyle Libre 3 Plus
Oct 29, 2025 • Drug Delivery Business
Market Might Still Lack Some Conviction On Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Even After 26% Share Price Boost
Oct 29, 2025 • simplywall.st
Tandem Diabetes Care (TNDM): Evaluating Valuation After Stifel Review and New Product Launches
Oct 21, 2025 • Yahoo Finance
Tandem Diabetes Care (TNDM) Faces Device Scrutiny and Regulatory Optimism—Is Transparency the Key to Trust?
Oct 18, 2025 • Sahm
Tandem Diabetes Care (TNDM) Is Up 5.6% After Pump Correction Spurs Legal Scrutiny and Insider Buying – Has the Bull Case Changed?
Oct 18, 2025 • Yahoo Finance
Tandem Diabetes Care (TNDM): Evaluating Valuation Following Insulin Pump Correction and Heightened Legal Scrutiny
Oct 17, 2025 • simplywall.st
Tandem Diabetes Care Stock (TNDM) Opinions on FDA Clearance and Legal Concerns
Oct 16, 2025 • Quiver Quantitative
INVESTOR ALERT: Investigation of Tandem Diabetes Care, Inc. (TNDM) Announced by Holzer & Holzer, LLC
Oct 7, 2025 • GlobeNewswire
Why Analysts Are Reassessing Tandem Diabetes Care as Its Growth Story Evolves
Oct 6, 2025 • Yahoo Finance
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Sep 30, 2025 • GlobeNewswire
Tandem Diabetes Care’s t:slim X2 Pump Cleared for Use with Lilly’s Ultra-Rapid Lyumjev® Insulin
Sep 29, 2025 • HIT Consultant
Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States
Sep 29, 2025 • Business Wire
Tandem t:slim X2 pump cleared for use with Lilly’s Lyumjev ultra-rapid insulin
Sep 29, 2025 • Drug Delivery Business
Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States
Sep 29, 2025 • Yahoo Finance
Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today
Sep 25, 2025 • Yahoo Finance
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Sep 24, 2025 • The Rosen Law Firm PA
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Sep 24, 2025 • PR Newswire
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Sep 24, 2025 • MarketScreener
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Sep 23, 2025 • Morningstar.com
TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm
Sep 21, 2025 • Morningstar.com
TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm
Sep 21, 2025 • MarketScreener
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation
Sep 20, 2025 • Newsfile
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Sep 19, 2025 • The Rosen Law Firm PA
Levi & Korsinsky Investigates Tandem Diabetes Care, Inc. (TNDM) Over Potential Securities Fraud Allegations
Sep 19, 2025 • Newsfile
Why Tandem Diabetes (TNDM) Stock Is Up Today
Sep 18, 2025 • Yahoo Finance
Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels
Sep 17, 2025 • BioSpace
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation
Sep 17, 2025 • Newsfile
Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels
Sep 16, 2025 • Business Wire
Tandem reports positive outcomes for automated insulin delivery in type 2 regardless of C-peptide levels
Sep 16, 2025 • Drug Delivery Business
FDA MedWatch Notice: Tandem Issues Correction for Certain t:slim X2 Insulin Pumps
Sep 16, 2025 • AHCA/NCAL
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Sep 16, 2025 • The Rosen Law Firm PA
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation
Sep 16, 2025 • Newsfile
Tandem Issues Correction for Certain t:slim X2 Insulin Pumps
Sep 15, 2025 • fda.gov
FDA Tandem Diabetes Care Issues Correction For Certain TSlim X2 Insulin Pumps
Sep 15, 2025 • Reuters
Fda Tandem Diabetes Care Issues Correction For Certain TSlim X2 Insulin Pumps
Sep 15, 2025 • MarketScreener
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation
Sep 14, 2025 • Newsfile
Jim Cramer Calls Tandem Diabetes “Speculative Stock for Younger People”
Sep 13, 2025 • Yahoo Finance
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Sep 12, 2025 • The Rosen Law Firm PA
Jim Cramer: This Is The Right Time To Buy This Energy Stock
Sep 11, 2025 • Benzinga.com
Tandem Diabetes Care at Morgan Stanley Conference: Strategic Growth Plans
Sep 10, 2025 • Investing.com
Transcript : Tandem Diabetes Care, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-10-2025 09
Sep 10, 2025 • MarketScreener
Tandem Diabetes assumed with an Outperform at Oppenheimer
Sep 8, 2025 • thefly.com
Wearable Injectors Market Key Players Analysis, Opportunities and Growth Forecast to 2035
Sep 8, 2025 • PharmiWeb
Tandem wins nod in Canada for smartphone app to control t:slim X2 automated insulin pump
Sep 4, 2025 • Drug Delivery Business
Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones
Sep 4, 2025 • Business Wire
Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones
Sep 4, 2025 • MarketScreener
Tandem announces Health Canada authorization for t:slim mobile application
Sep 4, 2025 • thefly.com
Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones
Sep 4, 2025 • Morningstar.com
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
Sep 3, 2025 • Senseonics Holdings, Inc.
Smart Insulin Pens & Pumps Market to Hit USD 14.6 Bn by 2035, Growing at 8.5% CAGR from 2025 | TMR
Aug 26, 2025 • EIN Presswire
Diabetes Devices Market to Double to US$ 70.6 Bn by 2035, Fueling a Revolution in Personalized Patient Care | TMR Study
Aug 20, 2025 • EIN Presswire
Error with Tandem insulin pumps causes 700 adverse events, 59 injuries
Aug 18, 2025 • HealthExec
Tandem Diabetes Care’s SWOT analysis: stock faces challenges amid competitive pressures
Aug 14, 2025 • Investing.com
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Aug 14, 2025 • Business Wire
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Aug 14, 2025 • Morningstar.com
Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Aug 14, 2025 • Business Wire
Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Aug 14, 2025 • MarketScreener
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Aug 14, 2025 • MarketScreener
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Aug 14, 2025 • Business Wire
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Aug 13, 2025 • Morningstar.com
Wearable Diabetes Device Market is Projected to Reach USD 42.1 Billion, with a Robust 9.5% CAGR Till 2035
Aug 13, 2025 • EIN Presswire
Tandem Diabetes stock upgraded at Citi (TNDM:NASDAQ)
Aug 12, 2025 • Seeking Alpha
5 Insightful Analyst Questions From Tandem Diabetes’s Q2 Earnings Call
Aug 12, 2025 • Yahoo Finance
Tandem Diabetes Care Stock (TNDM) Opinions on Q2 2025 Earnings Miss
Aug 12, 2025 • Quiver Quantitative
Tandem Diabetes at Canaccord Conference: Strategic Shifts and Market Focus
Aug 12, 2025 • Investing.com
CFRA slashes Tandem Diabetes Care stock price target on GLP-1 risks
Aug 11, 2025 • Investing.com
Tandem Diabetes Care Inc. (TNDM) - Product Pipeline Analysis Report 2025
Aug 11, 2025 • Research and Markets
Top 3 Health Care Stocks That Are Preparing To Pump This Month
Aug 11, 2025 • Benzinga.com
Tandem Diabetes Care: Earnings Miss Confirms Bear Case - Downgrade To Sell (NASDAQ:TNDM)
Aug 10, 2025 • Seeking Alpha
Tandem, Insulet monitoring CMS payment proposal for diabetes tech
Aug 8, 2025 • MedTech Dive
Tandem Diabetes Care Second Quarter 2025 Earnings: EPS Misses Expectations
Aug 8, 2025 • simplywall.st
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps
Aug 7, 2025 • Yahoo Finance
Earnings call transcript: Tandem Diabetes Care Q2 2025 misses EPS expectations
Aug 7, 2025 • Investing.com
Tandem insulin pump malfunction linked to 59 injuries
Aug 7, 2025 • MedTech Dive
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps
Aug 7, 2025 • Business Wire
Tandem Diabetes Care issues voluntary device correction for certain insulin pumps
Aug 7, 2025 • Reuters
Tandem Diabetes Care Inc issues voluntary medical device correction for select T:slim X2 insulin pumps
Aug 7, 2025 • MarketScreener
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock
Aug 7, 2025 • Benzinga.com
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Aug 7, 2025 • Benzinga.com
Tandem Diabetes Care Q2 2025 slides: dual-platform strategy targets underpenetrated market
Aug 6, 2025 • Investing.com
Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance
Aug 6, 2025 • Yahoo Finance
TANDEM DIABETES CARE Earnings Results: $TNDM Reports Quarterly Earnings
Aug 6, 2025 • Quiver Quantitative
Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance
Aug 6, 2025 • Business Wire
Tandem Diabetes Care Inc reports results for the quarter ended June 30 - Earnings Summary
Aug 6, 2025 • Reuters
Electronic Drug Delivery Systems Market
Aug 6, 2025 • PharmiWeb
Bears are Losing Control Over Tandem Diabetes Care (TNDM), Here's Why It's a 'Buy' Now
Aug 5, 2025 • Yahoo Finance

Links

www.tandemdiabetes.comLinkedInX (Twitter)Crunchbase